PATENT CLAIM ANALYSIS

Application Number: 16185372
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.

Claim (Index 7):
The method of  claim 1 , further comprising determining a nomogram score of the subject.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 98.0
- Lexical Diversity: 1.79381
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15896818', '15199056', '15406472', '15896931', '13483176']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8031515552117848
- 35 USC 102 Novelty (BERT): 0.7101892725151814
- Combined Prediction Score: 0.7938553269421245
- Mean Citation Score: 669.81888
- Max Citation Score: 804.7446
- Similarity Product: 730.1863108990431

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test